tiprankstipranks
Analyst Profile
Followed by 74 other investors
.
Carol Werther

Carol Werther

Dawson James
Wall Street Analyst
Ranked #163 out of 8,014 Analysts on TipRanks (#215 out of 21,455 overall experts)

Success Rate

57%
36 out of 63 Profitable Transactions

Average Return

56.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Carol Werther's ratings since 2012 and opened each position for the duration of 1 Year:
57.14% of your transactions would have been profitable with an average return of 56.6%

Stock Rating Distribution

76Ratings
86.84% Buy
13.16% Hold
0.00% Sell
Distribution of Carol Werther's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Viking Therapeutics
(VKTX)
Rating Type:Buy
Dates:Aug 10, 2017 - Aug 10, 2018
Gain:800.00%
The most profitable rating made by Carol Werther

Carol Werther's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Anthera Pharmaceuticals
Buy
Initiated
$15.00
(14999900.00% Upside)
0%
-90.40%
1
NPS Pharma
Buy
Reiterated
0%
-25.10%
1
Vertex Pharmaceuticals
Hold
Downgraded
0.00%
1
Ariad
Hold
Reiterated
0.00%
3
ImmunoCellular Therapeutics
Buy
Reiterated
$7.50
(1053.85% Upside)
0%
-25.00%
1
Amag Pharmaceuticals
Buy
Reiterated
100%
+78.23%
4
Rockwell Med
Buy
Reiterated
60%
+19.44%
5
Avanir Pharmaceuticals
Buy
Reiterated
100%
+200.47%
4
Northwest Biotherapeutics
Buy
Reiterated
$15.10
(2223.08% Upside)
100%
+33.20%
2
BioMarin Pharmaceutical
Buy
Reiterated
$84.00
(-12.68% Downside)
100%
+91.70%
1
List of latest recommendations made by Carol Werther. Click to expand and see Carol Werther's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More